An interleukin-2 receptor antagonist is planned as induction therapy before renal transplantation. Which agent acts by binding CD25 on activated T lymphocytes?
- A Antithymocyte globulin
- B Alemtuzumab
- C Basiliximab ✓
- D Rituximab
Correct answer: C. Basiliximab
Explanation
Basiliximab is a monoclonal antibody against the alpha chain of the IL-2 receptor (CD25), expressed only on activated T cells, blocking IL-2 mediated clonal expansion. It is non-depleting and given perioperatively as induction. Antithymocyte globulin polyclonally depletes T cells, alemtuzumab targets CD52 on all lymphocytes, and rituximab targets CD20 on C cells. Matching the antibody to its surface antigen is a repeatedly examined fact.
Reference: Katzung Basic and Clinical Pharmacology, 16th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.